Literature DB >> 22851270

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

Yusuke Nakamura, Mark J Ratain, Nancy J Cox, Howard L McLeod, Deanna L Kroetz, David A Flockhart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22851270     DOI： 10.1093/jnci/djs304

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  29 in total

1.  Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.

Authors:  Daniel L Hertz; Kelley M Kidwell; Jacklyn N Thibert; Christina Gersch; Meredith M Regan; Todd C Skaar; N Lynn Henry; Daniel F Hayes; Catherine H Van Poznak; James M Rae
Journal:  Mol Oncol       Date:  2015-07-29       Impact factor: 6.603

2.  CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

Authors:  D L Hertz; K M Kidwell; S G Hilsenbeck; S Oesterreich; C K Osborne; S Philips; C Chenault; R J Hartmaier; T C Skaar; M J Sikora; J M Rae
Journal:  Breast Cancer Res Treat       Date:  2017-07-20       Impact factor: 4.872

3.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Authors:  Hiltrud Brauch; Werner Schroth; Matthew P Goetz; Thomas E Mürdter; Stefan Winter; James N Ingle; Matthias Schwab; Michel Eichelbaum
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

4.  Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors:  Matthew P Goetz; Hiltrud Brauch; Mark J Ratain; Nancy J Cox; Yusuke Nakamura; Richard Weinshilboum; James N Ingle
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

5.  Sources of error in the retracted scientific literature.

Authors:  Arturo Casadevall; R Grant Steen; Ferric C Fang
Journal:  FASEB J       Date:  2014-06-13       Impact factor: 5.191

Review 6.  Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.

Authors:  Thomas P Ahern; Daniel L Hertz; Per Damkier; Bent Ejlertsen; Stephen J Hamilton-Dutoit; James M Rae; Meredith M Regan; Alastair M Thompson; Timothy L Lash; Deirdre P Cronin-Fenton
Journal:  Am J Epidemiol       Date:  2016-12-17       Impact factor: 4.897

Review 7.  Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.

Authors:  G S Hwang; R Bhat; R D Crutchley; M V Trivedi
Journal:  Pharmacogenomics J       Date:  2017-08-01       Impact factor: 3.550

Review 8.  Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

Authors:  Deirdre P Cronin-Fenton; Per Damkier; Timothy L Lash
Journal:  Future Oncol       Date:  2014-01       Impact factor: 3.404

9.  Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Authors:  Matthew P Goetz; James X Sun; Vera J Suman; Grace O Silva; Charles M Perou; Yusuke Nakamura; Nancy J Cox; Philip J Stephens; Vincent A Miller; Jeffrey S Ross; David Chen; Stephanie L Safgren; Mary J Kuffel; Matthew M Ames; Krishna R Kalari; Henry L Gomez; Ana M Gonzalez-Angulo; Octavio Burgues; Hiltrud B Brauch; James N Ingle; Mark J Ratain; Roman Yelensky
Journal:  J Natl Cancer Inst       Date:  2014-12-08       Impact factor: 13.506

Review 10.  Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.

Authors:  Keith T Schmidt; Cindy H Chau; Douglas K Price; William D Figg
Journal:  J Clin Pharmacol       Date:  2016-06-17       Impact factor: 3.126
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.